Fig 2: Twenty most abundant proteins in capsule specimens from cataract patients (CAT) or cataract patients with XFS or XFG. The 20 proteins account for approximately 70% of the total protein in each case. Note that the composition of the CAT and XFS/XFG samples is quite similar, although FBN1 (*) is visibly increased in the latter.

Fig 3: Immunofluorescence localization of LOXL1 and FBN1 on the surface of a lens capsule specimen from a patient with XFS (#K28). (A–C) Both LOXL1 (red) and FBN1 (green) label XFM in the central disc (CD) and granular zone (GZ). The clear zone (CZ), which lacks XFM, is unlabeled. The two immunofluorescence signals largely overlap, as shown in the merged image (C). However, high magnification images (D–F) of an individual XFM aggregate from the GZ shows that the two proteins are not precisely colocalized. Similarly, antibodies to the N-terminal (G; green) or C-terminal (H; red) regions of LOXL1 label XFM aggregates but the two signals only partially overlap (I).

Fig 4: Localization of FBN1, LTBP-2 and (MFAP2) in aggregates of exfoliation material on the surface of a lens capsules from an XFG patient (#S48).